Existing investor Novartis has committed to a $10m private placement alongside the IPO, in which the fibrosis therapy developer, based on UCSF research, is set to raise up to $96m.
Nanoform has filed for a dual listing in Sweden and Finland, marking the first time that a University of Helsinki spinout is seeking an initial public offering.
Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.
Chinese Academy of Sciences and its VC subsidiary TCL Capital are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.
University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.
The Chalmers University of Technology back pain injection spinout floated in an IPO that was oversubscribed by more than four-fold.
The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.
The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.